TapewireFind a company

person · Reporting owner

Rosenkranz Roberto Pedro

Disclosed activity across 1 company

Tapewire entity
148538
SEC CIK
0001621332

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
KYNTRA BIO, INC.FGEN · Entity 7431DirectorJune 09, 2020June 12, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

KYNTRA BIO, INC.

Report date June 09, 2020 · Filed June 12, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect96,100 Ending reported balance After 2020-06-09 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2020-06-09 · Exercise / conversion · Acquired 12,000 · Balance 84,100

Row 2 · 2020-06-09 · Exercise / conversion · Acquired 12,000 · Balance 96,100

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.65 · Expires 2027-06-07Direct0 Reported balance After 2020-06-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-06-09 · Exercise / conversion · Disposed 12,000 · Balance 0

F1: Fully vested.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.05 · Expires 2026-06-08Direct0 Reported balance After 2020-06-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-06-09 · Exercise / conversion · Disposed 12,000 · Balance 0

F1: Fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: Fully vested.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 09, 2020 Filed Jun 12, 2020 01:22 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 12,000 $0.00 Strike: $19.05 $0.00
Disclosure

SEC source: 0001209191-20-036173 · doc4.xml · derivative · entry 4

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2026-06-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Fully vested.

Read SEC document
June 09, 2020 Filed Jun 12, 2020 01:22 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 12,000 $0.00 Strike: $28.65 $0.00
Disclosure

SEC source: 0001209191-20-036173 · doc4.xml · derivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2027-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Fully vested.

Read SEC document
June 09, 2020 Filed Jun 12, 2020 01:22 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 12,000 $19.05 $228,600.00
Disclosure

SEC source: 0001209191-20-036173 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 09, 2020 Filed Jun 12, 2020 01:22 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 12,000 $28.65 $343,800.00
Disclosure

SEC source: 0001209191-20-036173 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 04, 2020 Filed Jun 9, 2020 00:33 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantStock Option (Right to Buy) · Derivative 7,800 $0.00 Strike: $32.69 $0.00
Disclosure

SEC source: 0001209191-20-035157 · doc4.xml · derivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2030-06-03

F2 · derivative.exercise_date: Options vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

Read SEC document
June 04, 2020 Filed Jun 9, 2020 00:33 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantCommon Stock 4,700 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-035157 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,100

F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

Read SEC document
June 05, 2019 Filed Jun 7, 2019 23:21 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantStock Option (Right to Buy) · Derivative 7,800 $0.00 Strike: $39.03 $0.00
Disclosure

SEC source: 0001209191-19-035665 · doc4.xml · derivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2029-06-05

F2 · derivative.exercise_date: Options vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders.

Read SEC document
June 05, 2019 Filed Jun 7, 2019 23:21 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantCommon Stock 4,700 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-035665 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,400

F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders.

Read SEC document
May 15, 2019 Filed May 17, 2019 20:49 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 12,000 $0.00 Strike: $18.34 $0.00
Disclosure

SEC source: 0001209191-19-031002 · doc4.xml · derivative · entry 6

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2025-06-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Fully vested.

Read SEC document
May 15, 2019 Filed May 17, 2019 20:49 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 12,000 $0.00 Strike: $18.00 $0.00
Disclosure

SEC source: 0001209191-19-031002 · doc4.xml · derivative · entry 5

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2024-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Fully vested.

Read SEC document
May 15, 2019 Filed May 17, 2019 20:49 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 6,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-19-031002 · doc4.xml · derivative · entry 4

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Fully vested.

Read SEC document
May 15, 2019 Filed May 17, 2019 20:49 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 12,000 $18.34 $220,080.00
Disclosure

SEC source: 0001209191-19-031002 · doc4.xml · nonDerivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2019 Filed May 17, 2019 20:49 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 12,000 $18.00 $216,000.00
Disclosure

SEC source: 0001209191-19-031002 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2019 Filed May 17, 2019 20:49 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 6,000 $9.78 $58,650.00
Disclosure

SEC source: 0001209191-19-031002 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 20, 2018 Filed Dec 21, 2018 21:22 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-18-063915 · doc4.xml · derivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
December 20, 2018 Filed Dec 21, 2018 21:22 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 1,000 $41.00 $41,000.00
Disclosure

SEC source: 0001209191-18-063915 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,700

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

Read SEC document
December 20, 2018 Filed Dec 21, 2018 21:22 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 1,000 $9.78 $9,775.00
Disclosure

SEC source: 0001209191-18-063915 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 15, 2018 Filed Nov 16, 2018 23:28 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-18-059052 · doc4.xml · derivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Underlying: Common Stock · 1,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
November 15, 2018 Filed Nov 16, 2018 23:28 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 1,000 $39.24 $39,240.00
Disclosure

SEC source: 0001209191-18-059052 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,700

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

Read SEC document
November 15, 2018 Filed Nov 16, 2018 23:28 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 1,000 $9.78 $9,775.00
Disclosure

SEC source: 0001209191-18-059052 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 18, 2018 Filed Oct 20, 2018 00:41 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-18-055805 · doc4.xml · derivative · entry 4

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 1,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully vested.

Read SEC document
October 18, 2018 Filed Oct 20, 2018 00:41 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 936 $55.49 $51,938.64
Disclosure

SEC source: 0001209191-18-055805 · doc4.xml · nonDerivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,700

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

F2 · price: The shares were sold at prices ranging from $55.30 and $55.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
October 18, 2018 Filed Oct 20, 2018 00:41 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 64 $53.89 $3,448.64
Disclosure

SEC source: 0001209191-18-055805 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,636

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

Read SEC document
October 18, 2018 Filed Oct 20, 2018 00:41 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 1,000 $9.78 $9,775.00
Disclosure

SEC source: 0001209191-18-055805 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 20, 2018 Filed Sep 21, 2018 22:16 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-18-051975 · doc4.xml · derivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 1,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
September 20, 2018 Filed Sep 21, 2018 22:16 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 1,000 $56.95 $56,950.00
Disclosure

SEC source: 0001209191-18-051975 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,700

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

Read SEC document
September 20, 2018 Filed Sep 21, 2018 22:16 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 1,000 $9.78 $9,775.00
Disclosure

SEC source: 0001209191-18-051975 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 16, 2018 Filed Aug 17, 2018 21:28 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-18-047486 · doc4.xml · derivative · entry 4

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 1,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

Read SEC document
August 16, 2018 Filed Aug 17, 2018 21:28 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 580 $60.64 $35,171.20
Disclosure

SEC source: 0001209191-18-047486 · doc4.xml · nonDerivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,700

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

F3 · price: The shares were sold at prices ranging from $60.35 and $61.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
August 16, 2018 Filed Aug 17, 2018 21:28 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 420 $59.78 $25,107.60
Disclosure

SEC source: 0001209191-18-047486 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,280

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

F2 · price: The shares were sold at prices ranging from $59.35 and $60.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
August 16, 2018 Filed Aug 17, 2018 21:28 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 1,000 $9.78 $9,775.00
Disclosure

SEC source: 0001209191-18-047486 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 19, 2018 Filed Jul 20, 2018 22:10 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-18-043517 · doc4.xml · derivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 1,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
July 19, 2018 Filed Jul 20, 2018 22:10 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 1,000 $64.90 $64,900.00
Disclosure

SEC source: 0001209191-18-043517 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,700

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

Read SEC document
July 19, 2018 Filed Jul 20, 2018 22:10 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 1,000 $9.78 $9,775.00
Disclosure

SEC source: 0001209191-18-043517 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 21, 2018 Filed Jun 22, 2018 21:48 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-18-039294 · doc4.xml · derivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 1,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
June 21, 2018 Filed Jun 22, 2018 21:48 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 1,000 $63.65 $63,650.00
Disclosure

SEC source: 0001209191-18-039294 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,700

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

Read SEC document
June 21, 2018 Filed Jun 22, 2018 21:48 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 1,000 $9.78 $9,775.00
Disclosure

SEC source: 0001209191-18-039294 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 05, 2018 Filed Jun 7, 2018 23:41 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantStock Option (Right to Buy) · Derivative 6,000 $0.00 Strike: $55.30 $0.00
Disclosure

SEC source: 0001209191-18-036518 · doc4.xml · derivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2028-06-05

F2 · derivative.exercise_date: Options vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders.

Read SEC document
June 05, 2018 Filed Jun 7, 2018 23:41 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantCommon Stock 3,700 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-036518 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,700

F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders.

Read SEC document
May 17, 2018 Filed May 18, 2018 20:07 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-18-031382 · doc4.xml · derivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 1,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
May 17, 2018 Filed May 18, 2018 20:07 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 1,000 $52.20 $52,200.00
Disclosure

SEC source: 0001209191-18-031382 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,000

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

Read SEC document
May 17, 2018 Filed May 18, 2018 20:07 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 1,000 $9.78 $9,775.00
Disclosure

SEC source: 0001209191-18-031382 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 19, 2018 Filed Apr 20, 2018 22:29 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-18-025748 · doc4.xml · derivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 1,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully vested.

Read SEC document
April 19, 2018 Filed Apr 20, 2018 22:29 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 1,000 $47.70 $47,700.00
Disclosure

SEC source: 0001209191-18-025748 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,000

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

F2 · price: The shares were sold at prices ranging from $47.30 and $48.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
April 19, 2018 Filed Apr 20, 2018 22:29 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 1,000 $9.78 $9,775.00
Disclosure

SEC source: 0001209191-18-025748 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 15, 2018 Filed Mar 16, 2018 22:04 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-18-020343 · doc4.xml · derivative · entry 4

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 1,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

Read SEC document
March 15, 2018 Filed Mar 16, 2018 22:04 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 300 $52.78 $15,834.00
Disclosure

SEC source: 0001209191-18-020343 · doc4.xml · nonDerivative · entry 3

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,000

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

F3 · price: The shares were sold at prices ranging from $52.75 and $52.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 15, 2018 Filed Mar 16, 2018 22:04 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 700 $52.15 $36,505.00
Disclosure

SEC source: 0001209191-18-020343 · doc4.xml · nonDerivative · entry 2

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,300

F1 · kind: Shares sold pursuant to a 10b5-1 Plan.

F2 · price: The shares were sold at prices ranging from $51.75 and $52.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 15, 2018 Filed Mar 16, 2018 22:04 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionCommon Stock 1,000 $9.78 $9,775.00
Disclosure

SEC source: 0001209191-18-020343 · doc4.xml · nonDerivative · entry 1

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 15, 2018 Filed Feb 16, 2018 22:53 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Exercise / conversionStock Option (Right to Buy) · Derivative 1,000 $0.00 Strike: $9.78 $0.00
Disclosure

SEC source: 0001209191-18-010949 · doc4.xml · derivative · entry 4

Rosenkranz Roberto Pedro · CIK 0001621332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 1,000 shares

Expires 2023-04-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.